Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13304849 | 0.83 | KDM4E (0.38) | MEN1KMT2AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL10194200 | 0.81 | MEN1 (0.44) | MEN1KMT2AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1720771 | 0.77 | KDM4E (0.46) | MEN1KMT2AALDH1A1KDM4EGAA | |
| SCHEMBL30625419 | 0.77 | KDM4E (0.45) | ALDH1A1LMNAL3MBTL1MAPTKDM4E | |
| SCHEMBL12478684 | 0.74 | KMT2A (0.51) | KMT2AALDH1A1LMNAKDM4EGAA | |
| SCHEMBL1907083 | 0.74 | TSHR (0.56) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL1014580 | 0.73 | KDM4E (0.58) | MEN1KMT2AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL10466216 | 0.73 | TSHR (0.53) | MEN1KMT2AALDH1A1LMNAL3MBTL1 | |
| SCHEMBL798220 | 0.72 | NAPRT (0.45) | ALDH1A1MAPTKDM4ERAB9ATSHR | |
| SCHEMBL9808548 | 0.72 | KMT2A (0.49) | MEN1KMT2AALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552019-B2 | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552019-B2 | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552019-B2 | Inhibitors of phosphoinositide dependent kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2373636-A1 | INHIBITORS OF PHOSPHOINOSITIDE DEPENDENT KINASE 1 (PDK1) | Merck Sharp & Dohme Corp. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | MERCK SHARP & DOHME CORP. | 2011-09-22 | — | — | US | disclosed |
| US-6342504-B1 | PEPTIDES AS ANTITHROMBINS AND ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2002-01-29 | — | — | US | disclosed |
| US-6011158-A | PEPTIDE ALDEHYDE COMPOUNDS HAVING ARGININE OR ARGININE MIMICS AT P1 AND PYRIDONE, PYRIMIDONE, OR URACIL GROUPS AS PART OF THE PEPTIDE BACKBONE. THESE COMPOUNDS ARE POTENT INHIBITORS OF THROMBIN IN VIVO AND IN VITRO. | CORVAS INTERNATIONAL, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-6008351-A | PEPTIDE ALDEHYDE COMPOUNDS HAVING URACIL OR PYRIMIDIN-4-ONE GROUPS AS PART OF THE PEPTIDE BACKBONE; POTENT INHIBITORS OF THROMBIN | CORVAS INTERNATIONAL, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0588299-B1 | 1,2,4-Oxadiazolyl- or 1,2,4-thiadiazolyl-biphenyl derivatives as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0829479-A1 | Heterocyclic compounds and their use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5658930-A | THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5656645-A | INHIBITORS OF THROMBIN | CORVAS INTERNATIONAL, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | disclosed |
| US-5500427-A | ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-19 | — | — | US | disclosed |
| EP-0588299-A2 | 1,2,4-Oxadiazolyl- or 1,2,4-thiadiazolyl-biphenyl derivatives as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230500-A1 | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) | PDK1, PDPK1, PDK3 | MEN1 667/4885KMT2A 1001/4885ALDH1A1 2184/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | MEN1 755/4885KMT2A 1470/4885ALDH1A1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.